Altimmune, Inc. (ALT)
NASDAQ: ALT · Real-Time Price · USD
3.860
-0.020 (-0.52%)
At close: Mar 10, 2026, 4:00 PM EDT
3.870
+0.010 (0.26%)
After-hours: Mar 10, 2026, 7:59 PM EDT
Altimmune Employees
Altimmune had 57 employees as of December 31, 2025. The number of employees decreased by 2 or -3.39% compared to the previous year.
Employees
57
Change (1Y)
-2
Growth (1Y)
-3.39%
Revenue / Employee
$695
Profits / Employee
-$1,493,102
Market Cap
502.07M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 57 | -2 | -3.39% |
| Dec 31, 2024 | 59 | 0 | - |
| Dec 31, 2023 | 59 | 7 | 13.46% |
| Dec 31, 2022 | 52 | 5 | 10.64% |
| Dec 31, 2021 | 47 | 4 | 9.30% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| REGENXBIO | 371 |
| Rigel Pharmaceuticals | 174 |
| Prothena Corporation | 163 |
| Century Therapeutics | 150 |
| Kyverna Therapeutics | 129 |
| Invivyd | 100 |
| Lexeo Therapeutics | 61 |
| Atea Pharmaceuticals | 55 |
ALT News
- 5 days ago - Altimmune, Inc. (ALT) Q4 2025 Earnings Call Transcript - Seeking Alpha
- 5 days ago - Altimmune Announces Fourth Quarter and Full-year 2025 Financial Results and Business Updates - GlobeNewsWire
- 8 days ago - Altimmune to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 12 days ago - Altimmune to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on March 5, 2026 - GlobeNewsWire
- 5 weeks ago - Obesity stocks slump on Novo's underwhelming 2026 sales forecast - Reuters
- 5 weeks ago - Altimmune Announces Closing of $75 Million Registered Direct Offering of Common Stock - GlobeNewsWire
- 5 weeks ago - Altimmune (ALT) Shares Slide On $75 Million Stock Offering - Benzinga
- 5 weeks ago - Altimmune Announces Pricing of $75 Million Registered Direct Offering of Common Stock - GlobeNewsWire